PKM and prostate cancer: Serum-derived sEV PKM2, a glycolytic enzyme, from patients with either primary prostate cancer (PCa) or metastasis managed to create a PMN, suggesting that exosome PKM2 can be regarded as a novel clinical biomarker in PCa [108].